Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
March 07, 2024 16:12 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
March 04, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease
February 29, 2024 14:44 ET
|
American Kidney Fund
ROCKVILLE, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- The first day of March marks the beginning of Kidney Month, a month in which the American Kidney Fund (AKF) will mark 31 days of action that will...
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
February 14, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...